Valuation: Tenaya Therapeutics, Inc.

Market Cap 184M 162M 149M 138M 261M 17.59B 265M 1.78B 698M 8.66B 692M 677M 29.82B P/E 2026 *
-2.13x
P/E 2027 * -1.91x
Enterprise Value 88.35M 77.4M 71.37M 65.94M 125M 8.43B 127M 853M 334M 4.15B 332M 324M 14.28B EV / Sales 2026 *
10.4x
EV / Sales 2027 * -
Free-Float
99.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week+10.61%
Current month+17.76%
1 month+24.65%
3 months+26.14%
6 months+13.84%
Current year+22.33%
1 week 0.78
Extreme 0.7843
0.95
1 month 0.68
Extreme 0.68
0.95
Current year 0.53
Extreme 0.5316
1.15
1 year 0.53
Extreme 0.5316
2.35
3 years 0.36
Extreme 0.36
7.01
5 years 0.36
Extreme 0.36
32
10 years 0.36
Extreme 0.36
32
Manager TitleAgeSince
Chief Executive Officer 53 2018-05-31
Chief Tech/Sci/R&D Officer - 2024-06-26
Chief Tech/Sci/R&D Officer - 2018-09-30
Director TitleAgeSince
Chairman 77 2024-12-31
Director/Board Member 60 2020-02-29
Director/Board Member 59 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
May. 27Free

Director

120,000 0.0553%
May. 27Free

Founder

120,000 0.0553%
May. 27Free

Director

120,000 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%+10.61%+26.55%-84.35% 184M
+0.58%+2.06%+2.92%+10.86% 50.44B
-2.22%-1.25%+385.40%+586.81% 40.63B
-0.54%+0.39%+25.57%-5.28% 34.88B
-1.36%+0.35%+17.88%+55.14% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-1.81%-1.48% - - 17.11B
+0.51%-3.47%+63.97%+122.60% 15.29B
-9.37%-28.79%+37.45%+39.42% 10.62B
+0.23%-0.58%+13.76%+21.11% 13.74B
Average -1.04%-1.11%+64.22%+86.83% 24.29B
Weighted average by Cap. -0.88%-0.02%+84.11%+130.93%

Financials

2026 *2027 *
Net sales 8.51M 7.45M 6.87M 6.35M 12.04M 811M 12.24M 82.1M 32.2M 400M 31.94M 31.25M 1.38B -
Net income -85.78M -75.16M -69.3M -64.03M -121M -8.18B -123M -828M -325M -4.03B -322M -315M -13.87B -109M -95.33M -87.9M -81.22M -154M -10.38B -157M -1.05B -412M -5.11B -408M -400M -17.59B
Net Debt -96.1M -84.2M -77.63M -71.74M -136M -9.17B -138M -927M -364M -4.51B -361M -353M -15.54B -128M -112M -104M -95.73M -181M -12.23B -185M -1.24B -485M -6.02B -481M -471M -20.73B
Logo Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Employees
70
Date Price Change Volume
26-07-10 $0.8704 +2.40% 3,831,049
26-07-09 $0.8500 -3.40% 3,575,815
26-07-08 $0.8799 -4.36% 3,896,241
26-07-07 $0.9200 +6.31% 6,090,925
26-07-06 $0.8654 +9.98% 7,106,768
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
0.8500USD
Average target price
4.000USD
Spread / Average Target
+370.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNYA Stock